Pharmaceuticals News and Research

RSS

Celgene acquires Gloucester Pharmaceuticals

Celgene Corporation today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

18 Jan 2010

Study evaluates potential treatments for daytime sleepiness in head-injury patients

Local patients are being sought for a national clinical research study currently investigating a study medication for people who have had a head injury, concussion or bump on the head and feel sleepy or tired during the day.

13 Jan 2010

Shionogi receives approval to develop and commercialize intravenous peramivir in Japan

BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has received marketing and manufacturing approval for intravenous (i.v.) peramivir to treat patients with influenza in Japan.

13 Jan 2010

Webinar to assist pharmaceutical companies on how to measure effectiveness of Medication Guides

More than 80 Risk Evaluation and Mitigation Strategy (REMS) plans have been approved by the Food & Drug Administration since their inception in March 2008. Now, pharmaceutical companies must formally assess and report on how well these plans have actually been working in reducing drug risks, a mandated step in the REMS process.

13 Jan 2010

Era of rapid expansion in biomedical research funding began in 1990's ends

After a decade of remarkable growth, total annual funding for biomedical research in the U.S. has decelerated and may have even fallen when adjusted for inflation. That is the conclusion of a study today published in the Journal of the American Medical Association.

13 Jan 2010

UTEK announces new pricing model for its Pharmalicensing online service

UTEK Corporation, a leading IP licensing and innovation services company, is pleased to announce a new pricing model for its Pharmalicensing online service; the pricing will be effective starting January 13th.

13 Jan 2010

Scripps Research scientists produce chemically complex compound

In 1993 researchers discovered a chemical compound in a sponge off Palau, an island nation in the Pacific Ocean, that has shown anticancer, antibacterial, and antifungal pharmaceutical promise. But that wasn't its greatest allure, at least not for chemists.

13 Jan 2010

Study reveals potential opportunity for sponsors to reduce costs

A recent study by Cutting Edge Information focusing on compensation levels for clinical investigators reveals a potential opportunity for sponsors to reduce costs.

13 Jan 2010

Study indicates public and private funding for US biomedical research has decreased substantially

The rate of increase for funding of biomedical research in the U.S. has slowed since 2005, and the level of funding from the National Institutes of Health and industry appears to have decreased by 2 percent in 2008, after adjustment for inflation, according to an article in the January 13 issue of JAMA.

13 Jan 2010

Study finds financial ties between clinical study leaders and pharmaceutical companies

Reuters reports that a new study has found "cancer researchers who design clinical trials, analyze or interpret the data, or play other key scientific roles are four times more likely to have financial ties to industry than their counterparts who have lesser roles in these studies, such as recruiting study subjects or collecting the data."

13 Jan 2010

Pisgah Labs files its eighth patent application for technology to prevent prescription drug abuse

According to the Office of National Drug Control Policy, prescription drug abuse is more prevalent than abuse of cocaine, heroin and methamphetamine. In fact, in the past year, prescription drug abuse ranked second only to marijuana use. In the face of this growing problem, Pisgah Labs, Inc. has just filed its eighth patent application on a technology that promises to curb prescription drug abuse.

13 Jan 2010

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.

13 Jan 2010

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

13 Jan 2010

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

moksha8 and BioCryst today announced that moksha8 has been granted approval from COFEPRIS (The Federal Commission for the Protection against Sanitary Risk) in Mexico for the importation and use of peramivir in patients with influenza associated with the 2009 H1N1 influenza A strain.

13 Jan 2010

Kapa Biosystems signs non-exclusive North American distribution agreement with VWR International

Kapa Biosystems and VWR International, LLC announced today that they have entered into a non-exclusive North American distribution agreement for Kapa Biosystems' line of next-generation PCR reagents.

13 Jan 2010

Jiangbo Pharmaceuticals obtains renewal of Good Manufacturing Practices Certificate for Pharmaceutical Products

Jiangbo Pharmaceuticals, Inc. (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that one of its factories in China obtained a renewal of its Good Manufacturing Practices Certificate for Pharmaceutical Products ("GMP Certificate") from the State Food and Drug Administration (SFDA) for its tablets and granules.

13 Jan 2010

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.

13 Jan 2010

Microbix Biosystems signs partnership agreement with Therapure Biopharma

Microbix Biosystems Inc., a biotechnology company focused on virology and biological technologies, and Therapure Biopharma Inc., an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins, announced today the signing of a partnership agreement to manufacture and market water-based products to the pharmaceutical, biotechnology and other industries.

13 Jan 2010

NitricBio chooses Clinipace Worldwide to manage and conduct two phase 3 trials

Clinipace Worldwide, a global technology-driven clinical research organization (CRO), announced today that NitricBio has selected the company to manage and deploy multiple studies in support of medical applications of topical nitric oxide gas (gNO).

13 Jan 2010

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

Spherix Inc., an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the completion of patient enrollment in its global Phase 3 clinical trial NEET (70971-004), which is evaluating the safety and efficacy of D-tagatose as an oral treatment for Type 2 diabetes mellitus.

12 Jan 2010

Pharmaceuticals News and Research

Celgene acquires Gloucester Pharmaceuticals

Study evaluates potential treatments for daytime sleepiness in head-injury patients

Shionogi receives approval to develop and commercialize intravenous peramivir in Japan

Webinar to assist pharmaceutical companies on how to measure effectiveness of Medication Guides

Era of rapid expansion in biomedical research funding began in 1990's ends

UTEK announces new pricing model for its Pharmalicensing online service

Scripps Research scientists produce chemically complex compound

Study reveals potential opportunity for sponsors to reduce costs

Study indicates public and private funding for US biomedical research has decreased substantially

Study finds financial ties between clinical study leaders and pharmaceutical companies

Pisgah Labs files its eighth patent application for technology to prevent prescription drug abuse

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

Kapa Biosystems signs non-exclusive North American distribution agreement with VWR International

Jiangbo Pharmaceuticals obtains renewal of Good Manufacturing Practices Certificate for Pharmaceutical Products

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Microbix Biosystems signs partnership agreement with Therapure Biopharma

NitricBio chooses Clinipace Worldwide to manage and conduct two phase 3 trials

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence